• Diva Baggio, Eliza Chung, Cameron Wellard, Neil Waters, Tania Cushion, Geoffrey Chong, Tara Cochrane, Gavin Cull, Pratyush Giri, Nada Hamad, Anna Johnston, Denise Lee, Aarya Murali, Susan Morgan, Stephen Mulligan, Dipti Talaulikar, Sumita Ratnasingam, Erica Wood, Eliza Hawkes, and Stephen Opat.
• Olivia Newton-John Cancer Research and Wellness Centre, Austin Health, Melbourne, Victoria, Australia.
• Intern Med J. 2024 Jul 1; 54 (7): 122312271223-1227.

AbstractPopulation-based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age-standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow-up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0-35.3) and 4.6 (95% CI: 3.1-6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve.© 2024 The Author(s). Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.

31 keywords...

hide…